Characteristics of patients using bone-modifying therapy
| Characteristic . | Denosumab (n = 1725) . | Bisphosphonates (n = 1515) . |
|---|---|---|
| Age, y (mean [SD]) | 67.38 (10.65) | 69.38 (10.21) |
| Sex, male (%) | 906 (52.5) | 790 (52.1) |
| Race/ethnicity (%) | ||
| White | 953 (55.2) | 862 (56.9) |
| Black | 264 (15.3) | 275 (18.2) |
| Latinx | 161 (9.3) | 102 (6.7) |
| Asian | 40 (2.3) | 25 (1.7) |
| Other/unknown | 307 (17.8) | 251 (16.6) |
| 1L treatment type (%) | ||
| Chemo based | 116 (6.7) | 143 (9.4) |
| PI + iMiD based | 1069 (62.0) | 800 (52.8) |
| PI based | 84 (4.9) | 121 (8.0) |
| iMiD based | 89 (5.2) | 100 (6.6) |
| Other | 367 (21.3) | 351 (23.2) |
| eGFR <60 | 333 (25.6) | 414 (37.2) |
| Treated in community (%) | 1247 (72.3) | 1248 (82.4) |
| Transplant receipt | 66 (3.8) | 42 (2.8) |
| 0 HRCA | 799 (46.3) | 713 (47.1) |
| 1 HRCA | 183 (10.6) | 167 (11.0) |
| ≥2 HRCA | 34 (2.0) | 26 (1.7) |
| No FISH testing | 709 (41.1) | 609 (40.1) |
| Characteristic . | Denosumab (n = 1725) . | Bisphosphonates (n = 1515) . |
|---|---|---|
| Age, y (mean [SD]) | 67.38 (10.65) | 69.38 (10.21) |
| Sex, male (%) | 906 (52.5) | 790 (52.1) |
| Race/ethnicity (%) | ||
| White | 953 (55.2) | 862 (56.9) |
| Black | 264 (15.3) | 275 (18.2) |
| Latinx | 161 (9.3) | 102 (6.7) |
| Asian | 40 (2.3) | 25 (1.7) |
| Other/unknown | 307 (17.8) | 251 (16.6) |
| 1L treatment type (%) | ||
| Chemo based | 116 (6.7) | 143 (9.4) |
| PI + iMiD based | 1069 (62.0) | 800 (52.8) |
| PI based | 84 (4.9) | 121 (8.0) |
| iMiD based | 89 (5.2) | 100 (6.6) |
| Other | 367 (21.3) | 351 (23.2) |
| eGFR <60 | 333 (25.6) | 414 (37.2) |
| Treated in community (%) | 1247 (72.3) | 1248 (82.4) |
| Transplant receipt | 66 (3.8) | 42 (2.8) |
| 0 HRCA | 799 (46.3) | 713 (47.1) |
| 1 HRCA | 183 (10.6) | 167 (11.0) |
| ≥2 HRCA | 34 (2.0) | 26 (1.7) |
| No FISH testing | 709 (41.1) | 609 (40.1) |
Differences in eGFR expressed as a fraction of patients with available data.
eGFR, estimated glomerular filtration rate; FISH, fluorescence in situ hybridization; HRCA, high-risk cytogenetic abnormalities, defined as either of Gain1q, translocation 4;14, deletion 17p, translocation 14;20; iMiD, immunomodulatory drugs; PI, proteasome inhibitor.